David Back is Emeritus Professor of Pharmacology at the University of Liverpool and has led studies on Clinical Pharmacology and drug interactions of antiretrovirals and HCV drugs. David has authored ~500 publications, is a former Editor of British Journal of Clinical Pharmacology and is the scientific lead on the online resources eg www.hiv-druginteractions.org & www.hep-druginteractions.org. In 2007 he was awarded the BPS Lilly Prize for outstanding contribution to Clinical Pharmacology and in 2015 an EACS Lifetime achievement award.
At the completion of this educational session, learners will:
- Be aware of the increasing burden and complexity of multi-morbidity and polypharmacy in older HIV patients.
- Know about the basic mechanisms of drug-drug interactions and the inclusion of interaction data in the label.
- Appreciate the different interaction potential of antiretrovirals in our current guidelines and have a clear understanding of which interactions should always be on our radar!
- Have some understanding as to whether in the long acting era drug interactions will still be of concern!
This CME activity has approved for AMA PRA Category 1 Credit™
on August 20, 2019 and will terminate August 19, 2022.
The target audience is all physicians, NPs and PAs involved or interested in HIV education.
This online video and post-activity evaluation are one hour in length.
After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
You must achieve at least 70% correct to receive your CME certificate.
If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™
. Physicians should claim only the credit commensurate with extent of their participation in the activity.
Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.
Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose.
Dr. David J. Back (Presenter) has had the following personal financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity: Educational grants from Gilead, ViiV, Merck, Abbvie, and Janssen; speaker’s bureau honorarium from Gilead, ViiV, Merck, and Abbvie. Dr. Back submitted his slides in advance for adequate peer review, and will support his presentation and clinical recommendations with the best available evidence from the medical literature.
This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; and Merck & Co.
To obtain CME credit for this PRN program, please visit the PRN Courses Page
at the Clinical Education Initiative (CEI) web site. PRN and the Medical Society of the State of New York (MSSNY) jointly sponsor PRN enduring materials for CME, and provide them at no cost to the AIDS Institute of the New York State Department of Health (NYSDOH) for broadcast through the CEI. We thank the NYSDOH for making our CME programs available to a wider audience, and hope you will also browse the many other educational opportunities offered by the CEI.